文献速递骨质疏松与钙磷/甲状旁腺

PAX1 表观遗传异常改变参与甲状旁腺肿瘤发生

Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究探讨散发性甲状旁腺腺瘤中 PAX1 基因表达下调的表观遗传机制。在腺瘤组织中,PAX1 mRNA 和蛋白表达显著降低,其启动子区存在高甲基化(35%;14/40)及 H3K9ac 水平降低(6 倍;P < .004)。5'aza-2 脱氧胞苷处理大鼠甲状旁腺连续细胞可恢复 PAX1 表达,提示表观遗传失调参与 PHPT 发病。

要点

  • 甲状旁腺腺瘤中 PAX1 mRNA 和蛋白表达显著降低。
  • PAX1 启动子区高甲基化(35%;14/40)及 H3K9ac 降低(6 倍;P < .004)。
  • 5'aza-2 脱氧胞苷可恢复大鼠甲状旁腺细胞 PAX1 表达。

核心结论

  • PAX1 表达受表观遗传失调调控,参与散发性甲状旁腺腺瘤发生,并为 PHPT 提供临床与治疗启示。

研究设计与样本

  • 分析甲状旁腺腺瘤组织中 PAX1 的 DNA 甲基化(BSP)和组蛋白修饰(ChIP),并在大鼠甲状旁腺连续细胞中用 5'aza-2 脱氧胞苷处理。

主要发现

  • 甲状旁腺腺瘤中 PAX1 mRNA 和蛋白表达显著降低。
  • PAX1 启动子区高甲基化比例为 35%(14/40)。
  • PAX1 启动子区 H3K9ac 水平降低 6 倍(P < .004)。
  • 5'aza-2 脱氧胞苷处理大鼠甲状旁腺连续细胞后 PAX1 基因重新表达。

关键数值与推荐

  • PAX1 启动子区高甲基化:35%(14/40)。
  • PAX1 启动子区 H3K9ac 降低:6 倍;P < .004。

临床怎么用

  • 提示 PAX1 表观遗传改变可作为 PHPT 相关甲状旁腺肿瘤的潜在机制标志与治疗探索方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Primary hyperparathyroidism (PHPT) results from the hypersecretion of parathyroid hormone from parathyroid tumors. A transcription factor, namely Paired box1 (PAX1), is active in parathyroid gland development. OBJECTIVE: We aimed to study potential epigenetic-mediated mechanism of PAX1 gene in sporadic parathyroid adenomas. METHODS: In parathyroid adenomas tissues, we analyzed the DNA methylation via bisulfite-specific polymerase chain reaction (BSP) and histone modifications via chromatin immunoprecipitation in regulating the differential expression of PAX1. RESULTS: The results showed that mRNA and protein expression of PAX1 was significantly reduced in parathyroid adenomas. Bisulfite sequencing demonstrated hypermethylation in the promoter region of PAX1 (35%; 14/40) and lower levels of histone 3 lysine 9 acetylation (H3K9ac) were observed on the promoter region of PAX1 (6-fold; P < .004) in parathyroid adenomas. Furthermore, upon treatment with a pharmacologic inhibitor, namely 5'aza-2 deoxycytidine, in rat parathyroid continuous cells, we found re-expression of PAX1 gene. CONCLUSION: Our study not only reveals expression of PAX1 is epigenetically deregulated but also paves a way for clinical and therapeutic implications in patients with PHPT.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Singh P, Bhadada SK, Arya AK, et al. Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis. J Clin Endocrinol Metab. 2022. PMID: 34453169. doi:10.1210/clinem/dgab626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。